

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 17:13:17 ON 02 OCT 2008
FILE 'CAPLUS' ENTERED AT 17:13:17 ON 02 OCT 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.85	190.42

=> file reg

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.85	190.42

FILE 'REGISTRY' ENTERED AT 17:13:27 ON 02 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2008 HIGHEST RN 1056151-32-6
DICTIONARY FILE UPDATES: 1 OCT 2008 HIGHEST RN 1056151-32-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10568503-a.str



```

chain nodes :
16 17 18 19 20 21 22 23 24 25 26 27 28 29
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
2-6 5-16 5-19 16-17 16-18 19-20 19-21 20-22 22-23 22-24 22-27 24-25
24-26 25-29 27-28
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 8-12 9-10 9-15 10-11 12-13 13-14
14-15
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 19-20 19-21 20-22 24-26
exact bonds :
2-6 5-16 5-19 16-17 16-18 22-23 22-24 22-27 24-25 25-29 27-28
normalized bonds :
6-7 6-11 7-8 8-9 8-12 9-10 9-15 10-11 12-13 13-14 14-15

```

```


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS

```

L4 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\STNEXP\Queries\10568503-b.str



```

chain nodes :
16 17 18
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
2-6 5-16 16-17 16-18
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 8-12 9-10 9-15 10-11 12-13 13-14
14-15
exact/norm bonds :
2-3 16-17 16-18
exact bonds :
1-2 1-5 2-6 3-4 4-5 5-16
normalized bonds :
6-7 6-11 7-8 8-9 8-12 9-10 9-15 10-11 12-13 13-14 14-15
isolated ring systems :
containing 1 : 6 :

```

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS

L5 STRUCTURE UPLOADED

=> d 14

L4 HAS NO ANSWERS

L4 STR


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> d 15

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 14 sss full

FULL SEARCH INITIATED 17:14:01 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 31 TO ITERATE

100.0% PROCESSED 31 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L6 1 SEA SSS FUL L4

=> s 15 sss full

FULL SEARCH INITIATED 17:14:04 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 26 TO ITERATE

100.0% PROCESSED 26 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

L7 2 SEA SSS FUL L5

=> file capl

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

356.26

546.68

FILE 'CAPLUS' ENTERED AT 17:14:06 ON 02 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Oct 2008 VOL 149 ISS 14
FILE LAST UPDATED: 1 Oct 2008 (20081001/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 167

L67 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s 16

L8 1 L6

=> s 17

L9 1 L7

=> d 18 ibib

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:216805 CAPLUS

DOCUMENT NUMBER: 142:298096

TITLE: Preparation of carbamoylisoxazoles as caspase inhibitors

INVENTOR(S): Chang, Hye-Kyung; Oh, Yeong-Koo; Park, Cheol-Won; Jang, Yong-Jin; Park, Tae-Kyo; Kim, Sung-Sub; Kim, Min-Jung; Park, Mi-Jeong; Park, Jung-Gyu; Park, Hee-Dong; Min, Kyeong-sik; Lee, Tae-soo; Lee, Sang-kyun; Kim, Soo-hyeon; Jeong, Hee-kyung; Lee, Sun-hwa; Kim, Hwa-dong; Kim, Ae-ri; Park, Ki-sook; Shin, Hyun-ik; Choi, Hyeong-wook; Lee, Kyu-woong; Lee, Jae-hoon; Heo, Tae-ho; Kim, Ho-jun; Kwon, Tae-sik

PATENT ASSIGNEE(S): Lg Life Sciences Ltd., S. Korea

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005021516	A1	20050310	WO 2004-KR2139	20040826
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004268895	A1	20050310	AU 2004-268895	20040826
CA 2535711	A1	20050310	CA 2004-2535711	20040826
EP 1660464	A1	20060531	EP 2004-774400	20040826
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
TR 200600899	T2	20060921	TR 2006-899	20040826
CN 1842521	A	20061004	CN 2004-80024702	20040826
BR 2004013848	A	20061024	BR 2004-13848	20040826
JP 2007503429	T	20070222	JP 2006-524573	20040826
US 20060223848	A1	20061005	US 2006-568503	20060216
IN 2006CN00641	A	20070608	IN 2006-CN641	20060222
MX 2006PA02267	A	20060517	MX 2006-PA2267	20060224
NO 2006001362	A	20060324	NO 2006-1362	20060324
PRIORITY APPLN. INFO.:			KR 2003-59451	A 20030827
			WO 2004-KR2139	W 20040826
OTHER SOURCE(S):			CASREACT 142:298096; MARPAT 142:298096	
REFERENCE COUNT:	5		THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	

=> d 19 ibib

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:216805 CAPLUS

DOCUMENT NUMBER: 142:298096

TITLE: Preparation of carbamoylisoxazoles as caspase inhibitors

INVENTOR(S): Chang, Hye-Kyung; Oh, Yeong-Koo; Park, Cheol-Won; Jang, Yong-Jin; Park, Tae-Kyo; Kim, Sung-Sub; Kim, Min-Jung; Park, Mi-Jeong; Park, Jung-Gyu; Park, Hee-Dong; Min, Kyeong-sik; Lee, Tae-soo; Lee, Sang-kyun; Kim, Soo-hyeon; Jeong, Hee-kyung; Lee, Sun-hwa; Kim, Hwa-dong; Kim, Ae-ri; Park, Ki-sook; Shin, Hyun-ik; Choi, Hyeong-wook; Lee, Kyu-woong; Lee, Jae-hoon; Heo, Tae-ho; Kim, Ho-jun; Kwon, Tae-sik

PATENT ASSIGNEE(S): Lg Life Sciences Ltd., S. Korea

SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005021516	A1	20050310	WO 2004-KR2139	20040826
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

AU 2004268895	A1	20050310	AU 2004-268895	20040826
CA 2535711	A1	20050310	CA 2004-2535711	20040826
EP 1660464	A1	20060531	EP 2004-774400	20040826
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
TR 200600899	T2	20060921	TR 2006-899	20040826
CN 1842521	A	20061004	CN 2004-80024702	20040826
BR 2004013848	A	20061024	BR 2004-13848	20040826
JP 2007503429	T	20070222	JP 2006-524573	20040826
US 20060223848	A1	20061005	US 2006-568503	20060216
IN 2006CN00641	A	20070608	IN 2006-CN641	20060222
MX 2006PA02267	A	20060517	MX 2006-PA2267	20060224
NO 2006001362	A	20060324	NO 2006-1362	20060324
PRIORITY APPLN. INFO.:			KR 2003-59451	A 20030827
			WO 2004-KR2139	W 20040826
OTHER SOURCE(S): CASREACT 142:298096; MARPAT 142:298096				
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	4.82	551.50

FILE 'REGISTRY' ENTERED AT 17:17:23 ON 02 OCT 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2008 HIGHEST RN 1056151-32-6
 DICTIONARY FILE UPDATES: 1 OCT 2008 HIGHEST RN 1056151-32-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
 Uploading C:\Program Files\STNEXP\Queries\10568503-c.str



```

chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5
chain bonds :
5-6 5-10 6-7 6-8 7-11
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
2-3 6-7 6-8 7-11
exact bonds :
1-2 1-5 3-4 4-5 5-6 5-10
isolated ring systems :
containing 1 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 10:CLASS
11:CLASS


```

L10 STRUCTURE UPLOADED

=> d l10

L10 HAS NO ANSWERS

L10 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l10 sss full

FULL SEARCH INITIATED 17:17:36 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1277 TO ITERATE

100.0% PROCESSED 1277 ITERATIONS

SEARCH TIME: 00.00.01

461 ANSWERS

L11 461 SEA SSS FUL L10

=> file capl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

729.86

FILE 'CAPLUS' ENTERED AT 17:17:38 ON 02 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Oct 2008 VOL 149 ISS 14

FILE LAST UPDATED: 1 Oct 2008 (20081001/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l11

L12 23 L11

=> d l12 1-23 ibib hitstr

L12 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:1045991 CAPLUS

DOCUMENT NUMBER: 149:299832

TITLE: Combination therapy for the treatment of liver diseases

INVENTOR(S): Spada, Alfred P.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 38pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20080207605	A1	20080828	US 2008-72729	20080228
WO 2008106167	A1	20080904	WO 2008-US2592	20080227
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,			

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2007-904321P P 20070228

US 2007-937300P P 20070626

IT 847944-99-4 847944-99-4D, derivs. 1050400-73-1
 , Xyz 033mp 1050400-73-1D, derivs.

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(MMP inhibitors plus caspase inhibitors for treatment of liver
 diseases)

RN 847944-99-4 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-
 methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 847944-99-4 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-
 methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.



CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-1-[(1S)-1-naphthalenylcarbonyl]amino]ethyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Clc1cc(Cl)cc(C(=O)OCC(=O)SNC(=O)C2(Cc3ccccc3)COC2=C2N[C@@H](C)SNC(=O)c4ccc5ccccc45)c1

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-1-[(1S)-1-naphthalenylcarbonyl]amino]ethyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Clc1cc(Cl)cc(C(=O)OCC(=O)SC(=O)Nc2c(C(=O)OCC3C=CN(C3C)SNC(=O)c4ccc5ccccc45)c2)cc1

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008035316	A2	20080327	WO 2007-IB53855	20070922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM IN 2006DE02099 A 20080404 IN 2006-DE2099 20060922 PRIORITY APPLN. INFO.: IN 2006-DE2099 A 20060922				

OTHER SOURCE(S): MARPAT 148:379636


IT 1013394-05-2P, (5R)-3-[4-(Difluoromethoxy)-3-ethoxyphenyl]-5-methyl-N-((1R)-1-phenylethyl)-4,5-dihydroisoxazole-5-carboxamide
 1013394-06-3P, (5S)-3-[4-(Difluoromethoxy)-3-ethoxyphenyl]-5-methyl-N-((1R)-1-phenylethyl)-4,5-dihydroisoxazole-5-carboxamide
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 1,3,4-oxadiazoles as phosphodiesterase IV inhibitors for treating CNS and inflammatory diseases)
 RN 1013394-05-2 CAPLUS
 CN 5-Isioxazolecarboxamide, 3-[4-(difluoromethoxy)-3-ethoxyphenyl]-4,5-dihydro-5-methyl-N-[(1R)-1-phenylethyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1013394-06-3 CAPLUS
 CN 5-Isioxazolecarboxamide, 3-[4-(difluoromethoxy)-3-ethoxyphenyl]-4,5-dihydro-5-methyl-N-[(1R)-1-phenylethyl]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:330210 CAPLUS

DOCUMENT NUMBER: 146:337882

TITLE: Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase IV inhibitors

INVENTOR(S): Palle, Venakta P.; Balachandran, Sarala; Gupta, Nidhi; Khairnar, Vinayak Vasantrao; Ramaiah, Raghu; Ray, Abhijit; Dastidar, Sunanda Ghose

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 37pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007031838	A1	20070322	WO 2006-IB2494	20060911
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1934219	A1	20080625	EP 2006-808837	20060911
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
IN 2008DN02840	A	20080725	IN 2008-DN2840	20080404
PRIORITY APPLN. INFO.:			IN 2005-DE2522	A 20050916
			WO 2006-IB2494	W 20060911

OTHER SOURCE(S): MARPAT 146:337882

IT 929633-44-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of pyrazolopyridines as phosphodiesterase IV inhibitors)

RN 929633-44-3 CAPLUS

CN 5-Isioxazolecarboxamide, 3-[4-(cyclopentylamino)-1,3-dimethyl-1H-

pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N,5-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:284017 CAPLUS

DOCUMENT NUMBER: 146:337899

TITLE: Preparation of indazolyloxazoles as phosphodiesterase IV inhibitors.

INVENTOR(S): Palle, Venakta; Balachandran, Sarala; Baregama, Lalit Kumar; Chakladar, Saswati; Ramnani, Sarika; Muthukamal, Nagarajan; Ray, Abhijit; Dastidar, Sunanda G.

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 54pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007029077	A1	20070315	WO 2006-IB2369	20060830
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1928866	A1	20080611	EP 2006-795373	20060830
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
IN 2008DN02808	A	20080808	IN 2008-DN2808	20080403
PRIORITY APPLN. INFO.:			IN 2005-DE2378	A 20050905
			WO 2006-IB2369	W 20060830

OTHER SOURCE(S): MARPAT 146:337899

IT 929293-51-6P 929293-52-7P, 3-(1-Cyclopentyl-3-methyl-1H-indazol-6-yl)-5-methyl-N-propyl-4,5-dihydroisoxazole-5-carboxamide


929293-54-9P, 3-(1-Cyclopentyl-3-methyl-1H-indazol-6-yl)-N-methyl-5-[2-(methylamino)-2-oxoethyl]-4,5-dihydroisoxazole-5-carboxamide
 929293-55-0P, 3-(1-Cyclopentyl-3-methyl-1H-indazol-6-yl)-5-[2-oxo-2-(propylamino)ethyl]-N-propyl-4,5-dihydroisoxazole-5-carboxamide
 929293-57-2P 929293-60-7P, 3-(1-Cyclopentyl-3-ethyl-1H-indazol-6-yl)-N-methyl-5-[2-(methylamino)-2-oxoethyl]-4,5-dihydroisoxazole-5-carboxamide 929293-61-8P, 3-(1-Cyclopentyl-3-ethyl-1H-indazol-6-yl)-5-[2-oxo-2-(propylamino)ethyl]-N-propyl-4,5-dihydroisoxazole-5-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indazolyloxazoles as inhibitors of phosphodiesterase IV)


RN 929293-51-6 CAPLUS

CN 5-Isloxazolecarboxamide, 3-(1-cyclopentyl-3-methyl-1H-indazol-6-yl)-4,5-dihydro-N,5-dimethyl- (CA INDEX NAME)




RN 929293-52-7 CAPLUS

CN 5-Isloxazolecarboxamide, 3-(1-cyclopentyl-3-methyl-1H-indazol-6-yl)-4,5-dihydro-5-methyl-N-propyl- (CA INDEX NAME)




RN 929293-54-9 CAPLUS

CN 5-Isloxazoleacetamide, 3-(1-cyclopentyl-3-methyl-1H-indazol-6-yl)-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 929293-55-0 CAPLUS

CN 5-Isoxazoleacetamide, 3-(1-cyclopentyl-3-methyl-1H-indazol-6-yl)-4,5-dihydro-N-propyl-5-[(propylamino)carbonyl]- (CA INDEX NAME)




RN 929293-57-2 CAPLUS

CN 5-Isoxazolecarboxamide, 3-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-4,5-dihydro-N,5-dimethyl- (CA INDEX NAME)




RN 929293-60-7 CAPLUS

CN 5-Isoxazoleacetamide, 3-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)



RN 929293-61-8 CAPLUS
 CN 5-Isoxazoleacetamide, 3-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-4,5-dihydro-N-propyl-5-[(propylamino)carbonyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1175788 CAPLUS
 DOCUMENT NUMBER: 145:471511
 TITLE: Preparation of isoxazole-based phosphodiesterase inhibitors
 INVENTOR(S): Palle, Venkata; Balachandran, Sarala; Muthukama, Nagarajan; Ray, Abhijit; Dastidar, Sunanda Ghose
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
 SOURCE: PCT Int. Appl., 97pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117653	A1	20061109	WO 2006-IB1133	20060503
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,				

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 EP 1879884 A1 20080123 EP 2006-727571 20060503
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 IN 2007DN09223 A 20080118 IN 2007-DN9223 20071129
 PRIORITY APPLN. INFO.: IN 2005-DE1101 A 20050503
 WO 2006-IB1133 W 20060503

OTHER SOURCE(S): MARPAT 145:471511


IT 913984-54-0P 913984-57-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(claimed compound; preparation of isoxazole-based phosphodiesterase
 inhibitors)


RN 913984-54-0 CAPLUS

CN 5-Isoxazolecarboxamide, 4-[[5-[[[(3,5-dichloro-4-pyridinyl)amino]carbonyl]-
 2-methoxyphenoxy]methyl]-N-ethyl-4,5-dihydro-5-methyl- (CA INDEX NAME)



RN 913984-57-3 CAPLUS

CN 5-Isoxazolecarboxamide, 3-[[5-[[[(3,5-dichloro-4-pyridinyl)amino]carbonyl]-
 2-methoxyphenoxy]methyl]-4,5-dihydro-N,5-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:885566 CAPLUS

DOCUMENT NUMBER: 145:293032


TITLE: Isoxazole derivatives as cell adhesion inhibitors and
 their preparation and pharmaceutical compositions

INVENTOR(S): Sattigeri, Viswajanani J.; Palle, Venkata P.; Soni,
 Ajay; Naik, Keshav Prabhakar; Ray, Abhijit; Dastidar,

Sunanda G.
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 69pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006090234	A1	20060831	WO 2006-IB348	20060221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2005DE00381	A	20061201	IN 2005-DE381	20050222
PRIORITY APPLN. INFO.:			IN 2005-DE381	A 20050222
OTHER SOURCE(S): CASREACT 145:293032; MARPAT 145:293032				
IT 908248-54-4P 908248-55-5P 908248-56-6P				
908248-57-7P 908248-58-8P 908248-59-9P				
908248-60-2P 908248-61-3P 908248-62-4P				
908248-63-5P 908248-64-6P 908248-66-8P				
908248-67-9P 908248-69-1P 908248-70-4P				
908248-71-5P 908248-72-6P 908248-73-7P				
908248-74-8P 908248-75-9P 908248-76-0P				
908248-77-1P 908248-78-2P 908248-79-3P				
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of isoxazole derivs. as cell adhesion inhibitors)				
RN 908248-54-4 CAPLUS				
CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[(4,5-dihydro-5-methyl-3- phenyl-5-isoxazolyl)carbonyl]- (CA INDEX NAME)				

Absolute stereochemistry.




RN 908248-55-5 CAPLUS
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[(4,5-dihydro-5-methyl-3-
phenyl-5-isoxazolyl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 908248-56-6 CAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, α -[[[4,5-dihydro-5-methyl-3-phenyl-5-isoxazolyl)carbonyl]amino]-2',6'-dimethoxy-, (α S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 908248-57-7 CAPLUS
CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[[4,5-dihydro-5-methyl-3-(2-phenylethyl)-5-isoxazolyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 908248-58-8 CAPLUS
CN L-Phenylalanine, N-[[[3-(3-chlorophenyl)-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]-4-[(2,6-dichlorobenzoyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-59-9 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[3-(2-fluorophenyl)-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-60-2 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[3-(2,6-dimethoxyphenyl)-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 908248-61-3 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[4,5-dihydro-3-(2-

methoxyphenyl)-5-methyl-5-isoxazolyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-62-4 CAPLUS

CN L-Phenylalanine, N-[[3-(2-chlorophenyl)-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]-4-[(2,6-dichlorobenzoyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-63-5 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[3-(2,6-dichlorophenyl)-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-64-6 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[4,5-dihydro-5-methyl-3-(1-phenylethyl)-5-isoxazolyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-66-8 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[3-(3,4-dimethoxyphenyl)-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-67-9 CAPLUS


CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[4,5-dihydro-5-methyl-3-(4-methylphenyl)-5-isoxazolyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 908248-69-1 CAPLUS
 CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[4,5-dihydro-5-methyl-3-(8-quinolinyl)-5-isoxazolyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 908248-70-4 CAPLUS
 CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[4,5-dihydro-5-methyl-3-(2-thienyl)-5-isoxazolyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-71-5 CAPLUS

CN Benzeneacetic acid, α -[[[4,5-dihydro-5-methyl-3-phenyl-5-isoxazolyl)carbonyl]amino]-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-72-6 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[[5S)-4,5-dihydro-5-methyl-3-(5-quinolinyl)-5-isoxazolyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-73-7 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[[5R)-4,5-dihydro-5-methyl-3-(5-quinolinyl)-5-isoxazolyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-74-8 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[(5S)-4,5-dihydro-5-methyl-3-(3-pyridinyl)-5-isoxazolyl]carbonyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-75-9 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[(5R)-4,5-dihydro-5-methyl-3-(3-pyridinyl)-5-isoxazolyl]carbonyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-76-0 CAPLUS

CN L-Phenylalanine, N-[(3-cyclohexyl-4,5-dihydro-5-methyl-5-isoxazolyl)carbonyl]-4-[(2,6-dichlorobenzoyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-77-1 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[4,5-dihydro-5-methyl-3-(2-naphthalenyl)-5-isoxazolyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-78-2 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[[3-(1,1-dimethylethyl)-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-79-3 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[(4,5-dihydro-3,5-dimethyl-5-isoxazolyl)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 908248-80-6P 908248-86-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of isoxazole derivs. as cell adhesion inhibitors)

RN 908248-80-6 CAPLUS

CN L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[(4,5-dihydro-5-methyl-3-phenyl-5-isoxazolyl)carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 908248-86-2 CAPLUS

CN 5-Isoxazolecarboxamide, 3-cyclohexyl-N-[(1S)-2-[4-[(2,6-dichlorobenzoyl)amino]phenyl]-1-methoxyethyl]-4,5-dihydro-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:884384 CAPLUS

DOCUMENT NUMBER: 145:293030

TITLE: Preparation of isoxazoline derivatives as anti-inflammatory agents

INVENTOR(S): Shin, Hyun Ik; Choi, Hyeong Wook; Heo, Tae Ho; Lee, Kyu Woong; Lee, Jae Hoon; Park, Ki Sook

PATENT ASSIGNEE(S): Lg Life Sciences Ltd., S. Korea

SOURCE: PCT Int. Appl., 34pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006090997	A1	20060831	WO 2006-KR576	20060221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
KR 2006094868	A	20060830	KR 2006-13107	20060210
KR 774999	B1	20071109		
AU 2006217293	A1	20060831	AU 2006-217293	20060221
CA 2598347	A1	20060831	CA 2006-2598347	20060221
EP 1851214	A1	20071107	EP 2006-716026	20060221
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008531551	T	20080814	JP 2007-556969	20060221
KR 2007022842	A	20070227	KR 2007-13195	20070208
KR 747002	B1	20070807		
MX 200710338	A	20071011	MX 2007-10338	20070823
IN 2007CN03719	A	20071116	IN 2007-CN3719	20070824
CN 101128459	A	20080220	CN 2006-80005984	20070824
NO 2007004895	A	20071126	NO 2007-4895	20070926
PRIORITY APPLN. INFO.:			KR 2005-16203	A 20050226
			KR 2006-13107	A3 20060210
			WO 2006-KR576	W 20060221

OTHER SOURCE(S): CASREACT 145:293030; MARPAT 145:293030

IT 847944-99-4P 908253-61-2P 908253-62-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-dihydrofuranone isoxazoline carboxamide derivs. as anti-inflammatory agents)

RN 847944-99-4 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 908253-61-2 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4,4-dimethoxy-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 908253-62-3 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4,4-dimethoxy- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:295934 CAPLUS
 DOCUMENT NUMBER: 144:350690
 TITLE: Preparation of dicarbonylaminoisoxazoline derivatives as caspase inhibitors
 INVENTOR(S): Chang, Hye-Kyung; Oh, Yeong-Soo; Park, Cheol-Won; Jang, Yong-Jin; Kim, Sung-Sub; Kim, Min-Jung; Park, Mi-Jeong; Park, Jung-Gyu; Park, Tae-Kyo; Min, Kyeong-Sik; Lee, Tae-Soo; Lee, Sun-Hwa
 PATENT ASSIGNEE(S): LG Life Sciences Ltd., S. Korea
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006033551	A1	20060330	WO 2005-KR3136	20050922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: KR 2004-76788 A 20040924

IT 881182-75-8P 881182-76-9P 881182-77-0P
 881182-78-1P 881182-79-2P 881182-80-5P
 881182-81-6P 881182-82-7P 881182-83-8P
 881182-84-9P 881182-85-0P 881182-86-1P
 881182-87-2P 881182-88-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dicarbonylaminoisoxazoline derivs. as caspase inhibitors)

RN 881182-75-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[3-benzoyl-5-ethyl-4,5-dihydro-5-isoxazolyl)carbonyl]amino]-4-carboxy-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 881182-76-9 CAPLUS


CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-naphthalenylcarbonyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 881182-77-0 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-naphthalenylcarbonyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 881182-78-1 CAPLUS
 CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-isoquinolinylcarbonyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 881182-79-2 CAPLUS
 CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-[(1-naphthalenylamino)carbonyl]-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 881182-80-5 CAPLUS
 CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-[(1-naphthalenylamino)carbonyl]-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 881182-81-6 CAPLUS


CN Pentanoic acid, 3-[[[3-[[[1,1'-biphenyl]-2-ylamino)carbonyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 881182-82-7 CAPLUS

CN Pentanoic acid, 3-[[[3-[[[1,1'-biphenyl]-2-ylamino)carbonyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 881182-83-8 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-[[[2'-methyl[1,1'-biphenyl]-2-yl]amino]carbonyl]-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 881182-84-9 CAPLUS


CN Pentanoic acid, 3-[[[3-[(3,4-dihydro-1(2H)-quinolinyl)carbonyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 881182-85-0 CAPLUS


CN Pentanoic acid, 3-[[[3-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 881182-86-1 CAPLUS

CN Pentanoic acid, 3-[[[3-[[[2-(1,1-dimethylethyl)phenyl]amino]carbonyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 881182-87-2 CAPLUS

CN Pentanoic acid, 3-[[[3-[[[2-(1,1-dimethylethyl)phenyl]amino]carbonyl]-4,5-dihydro-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-
(CA INDEX NAME)



RN 881182-88-3 CAPLUS

CN Pentanoic acid, 3-[[[3-[[[2,5-bis(1,1-dimethylethyl)phenyl]amino]carbonyl]-4,5-dihydro-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-
(CA INDEX NAME)



IT 881182-91-8P 881182-92-9P 881182-95-2P

881182-96-3P 881182-97-4P 881182-98-5P

881183-02-4P 881183-05-7P 881183-07-9P

881183-09-1P 881183-11-5P 881183-13-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of dicarbonylaminoisoxazoline derivs. as caspase inhibitors)

RN 881182-91-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[3-benzoyl-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 881182-92-9 CAPLUS

CN D-glycero-Pentonic acid, 3-[[[3-benzoyl-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-2,3-dideoxy-, 1,1-dimethylethyl ester, 5-(2,6-dichlorobenzoate), (4ξ)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 881182-95-2 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-naphthalenylcarbonyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 881182-96-3 CAPLUS

CN D-glycero-Pentonic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-


naphthalenylcarbonyl)-5-isoxazolyl]carbonyl]amino]-2,3-dideoxy-5-O-phenyl-, 1,1-dimethylethyl ester, (4ξ)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 881182-97-4 CAPLUS


CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-naphthalenylcarbonyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 881182-98-5 CAPLUS

CN L-glycero-Pentonic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-naphthalenylcarbonyl)-5-isoxazolyl]carbonyl]amino]-2,3,5-trideoxy-5-fluoro-, 1,1-dimethylethyl ester, (4ξ)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881183-02-4 CAPLUS
 CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-isoquinolinylcarbonyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 881183-05-7 CAPLUS
 CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-[(1-naphthalenylamino)carbonyl]-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 881183-07-9 CAPLUS


CN Pentanoic acid, 3-[[[3-[[[1,1'-biphenyl]-2-ylamino)carbonyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 881183-09-1 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-[[[2'-methyl[1,1'-biphenyl]-2-yl)amino]carbonyl]-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 881183-11-5 CAPLUS


CN Pentanoic acid, 3-[[[3-[(3,4-dihydro-1(2H)-quinolinyl)carbonyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 881183-13-7 CAPLUS

CN Pentanoic acid, 3-[[[3-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:151203 CAPLUS

DOCUMENT NUMBER: 144:233059

TITLE: Preparation of heterocyclic derivatives as anti-inflammatory agents

INVENTOR(S): Palle, Venkata P.; Verma, Ashwani Kumar; Salman, Mohammad; Singh, Rakesh Kumar; Waman, Yogesh Bhaskarrao; Sharma, Geeta; Ray, Abhijit

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006016237	A2	20060216	WO 2005-IB2292	20050802
WO 2006016237	A3	20060526		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-598621P P 20040804

OTHER SOURCE(S): MARPAT 144:233059

IT 876136-34-4P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid methylamide
876136-35-5P, 3-[3-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid methylamide
876136-40-2P, 3-[3-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid propylamide
876136-42-4P, 3-[3-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid (2-hydroxyethyl)amide
876136-43-5P, 3-[3-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid benzylamide
876136-44-6P, 3-[3-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid isopropylamide
876136-45-7P, 3-[3-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid ethylamide
876136-52-6P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid butylamide
876136-55-9P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid tert-butylamide
876136-56-0P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid N-(prop-2-ynyl)amide
876136-61-7P, 3-[2-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid methylamide
876136-62-8P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid isopropylamide
876136-64-0P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid benzylamide
876136-65-1P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid (2-hydroxyethyl)amide
876136-68-4P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid ethylamide
876136-69-5P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid propylamide
876136-75-3P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid (3-methylbutyl)amide
876136-76-4P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid N-(allyl)amide
876136-86-6P, 3-[2-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid propylamide
876136-87-7P, 3-[2-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid (2-hydroxyethyl)amide
876136-88-8P, 3-[2-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid ethylamide
876136-98-0P, 3-[3-[[4-(4-Fluorobenzyl)piperidin-1-yl]carbonyl]-4-methoxyphenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid methylamide


876137-02-9P, 4-[3-[[4-(4-Fluorobenzyl)piperidin-1-yl]carbonyl]-4-methoxyphenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid ethylamide
 876137-05-2P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid [2-(pyrrolidin-1-yl)ethyl]amide
 876137-06-3P, 3-[4-[(4-Benzylpiperidin-1-yl)carbonyl]phenyl]-5-methyl-4,5-dihydroisoxazole-5-carboxylic acid [3-(morpholin-4-yl)propyl]amide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [(piperidiny]carbonyl]phenyl isoxazole derivs. as anti-inflammatory agents)


RN 876136-34-4 CAPLUS

CN 5-Isoxazolecarboxamide, 4,5-dihydro-N,5-dimethyl-3-[4-[[4-(phenylmethyl)-1-piperidiny]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-35-5 CAPLUS

CN 5-Isoxazolecarboxamide, 4,5-dihydro-N,5-dimethyl-3-[3-[[4-(phenylmethyl)-1-piperidiny]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-40-2 CAPLUS

CN 5-Isoxazolecarboxamide, 4,5-dihydro-5-methyl-3-[3-[[4-(phenylmethyl)-1-piperidiny]carbonyl]phenyl]-N-propyl- (CA INDEX NAME)




RN 876136-42-4 CAPLUS

CN 5-Isoxazolecarboxamide, 4,5-dihydro-N-(2-hydroxyethyl)-5-methyl-3-[3-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-43-5 CAPLUS

CN 5-Isoxazolecarboxamide, 4,5-dihydro-5-methyl-N-(phenylmethyl)-3-[3-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-44-6 CAPLUS

CN 5-Isoxazolecarboxamide, 4,5-dihydro-5-methyl-N-(1-methylethyl)-3-[3-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-45-7 CAPLUS


CN 5-Isoxazolecarboxamide, N-ethyl-4,5-dihydro-5-methyl-3-[3-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-52-6 CAPLUS
 CN 5-Isoxazolecarboxamide, N-butyl-4,5-dihydro-5-methyl-3-[4-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-55-9 CAPLUS
 CN 5-Isoxazolecarboxamide, N-(1,1-dimethylethyl)-4,5-dihydro-5-methyl-3-[4-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)



RN 876136-56-0 CAPLUS
 CN 5-Isoxazolecarboxamide, 4,5-dihydro-5-methyl-3-[4-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 876136-61-7 CAPLUS
 CN 5-Isoxazolecarboxamide, 4,5-dihydro-N,5-dimethyl-3-[2-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-62-8 CAPLUS

CN 5-Isoxazolecarboxamide, 4,5-dihydro-5-methyl-N-(1-methylethyl)-3-[4-[[4-(phenylmethyl)-1-piperidiny]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-64-0 CAPLUS

CN 5-Isoxazolecarboxamide, 4,5-dihydro-5-methyl-N-(phenylmethyl)-3-[4-[[4-(phenylmethyl)-1-piperidiny]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-65-1 CAPLUS

CN 5-Isoxazolecarboxamide, 4,5-dihydro-N-(2-hydroxyethyl)-5-methyl-3-[4-[[4-(phenylmethyl)-1-piperidiny]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-68-4 CAPLUS

CN 5-Isioxazolecaboxamide, N-ethyl-4,5-dihydro-5-methyl-3-[4-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-69-5 CAPLUS

CN 5-Isioxazolecaboxamide, 4,5-dihydro-5-methyl-3-[4-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]-N-propyl- (CA INDEX NAME)




RN 876136-75-3 CAPLUS

CN 5-Isioxazolecaboxamide, 4,5-dihydro-5-methyl-N-(3-methylbutyl)-3-[4-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-76-4 CAPLUS

CN 5-Isioxazolecaboxamide, 4,5-dihydro-5-methyl-3-[4-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]-N-2-propen-1-yl- (CA INDEX NAME)




RN 876136-86-6 CAPLUS

CN 5-Isioxazolecaboxamide, 4,5-dihydro-5-methyl-3-[2-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]-N-propyl- (CA INDEX NAME)




RN 876136-87-7 CAPLUS

CN 5-Isioxazolecaboxamide, 4,5-dihydro-N-(2-hydroxyethyl)-5-methyl-3-[2-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-88-8 CAPLUS

CN 5-Isioxazolecaboxamide, N-ethyl-4,5-dihydro-5-methyl-3-[2-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)




RN 876136-98-0 CAPLUS

CN 5-Isioxazolecaboxamide, 3-[3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]carbonyl]-4-methoxyphenyl]-4,5-dihydro-N,5-dimethyl- (CA INDEX NAME)




RN 876137-02-9 CAPLUS

CN 5-Isioxazolecaboxamide, N-ethyl-4-[3-[[4-[(4-fluorophenyl)methyl]-1-piperidinyl]carbonyl]-4-methoxyphenyl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 876137-05-2 CAPLUS

CN 5-Isoxazolecarboxamide, 4,5-dihydro-5-methyl-3-[4-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 876137-06-3 CAPLUS

CN 5-Isoxazolecarboxamide, 4,5-dihydro-5-methyl-N-[3-(4-morpholinyl)propyl]-3-[4-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)



L12 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2005:921226 CAPLUS

DOCUMENT NUMBER: 143:381666

TITLE: Exploring the Scope of the 29G12 Antibody Catalyzed 1,3-Dipolar Cycloaddition Reaction

AUTHOR(S): Tokar, Jonathan D.; Tremblay, Martin R.; Yli-Kauhaluoma, Jari; Wentworth, Anita D.; Zhou, Bin;


Wentworth, Paul, Jr.; Janda, Kim D.
 CORPORATE SOURCE: Department of Chemistry and the Skaggs Institute for
 Chemical Biology, The Scripps Research Institute, La
 Jolla, CA, 92037, USA
 SOURCE: Journal of Organic Chemistry (2005), 70(20), 7810-7815
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:381666
 IT 866825-86-7P
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation)
 (29G12 antibody catalyzes enantioselective 1,3-dipolar cycloaddn.
 reaction)
 RN 866825-86-7 CAPLUS
 CN 5-Isoxazolecarboxamide, 3-[4-(acetylamino)phenyl]-4,5-dihydro-N,5-dimethyl-
 (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:417698 CAPLUS
 DOCUMENT NUMBER: 143:115143
 TITLE: Enantioselective Cycloadditions with
 α,β -Disubstituted Acrylimides
 AUTHOR(S): Sibi, Mukund P.; Ma, Zhihua; Itoh, Kennosuke;
 Prabakaran, Narayanasamy; Jasperse, Craig P.
 CORPORATE SOURCE: Department of Chemistry, North Dakota State
 University, Fargo, ND, 58105-5516, USA
 SOURCE: Organic Letters (2005), 7(12), 2349-2352
 CODEN: ORLEF7; ISSN: 1523-7060
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:115143
 IT 857636-32-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (enantioselective cycloaddns. with α,β -disubstituted
 acrylimides)
 RN 857636-32-9 CAPLUS
 CN 5-Isoxazolecarboxamide, N-benzoyl-4,5-dihydro-4,5-dimethyl-3-(2,4,6-
 trimethylphenyl)-, (4R,5R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 857636-31-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(enantioselective cycloaddns. with α,β -disubstituted
acrylimides)

RN 857636-31-8 CAPLUS

CN 5-Isioxazolecarboxamide, 4,5-dihydro-4,5-dimethyl-N-(2-methyl-1-oxopropyl)-
3-(2,4,6-trimethylphenyl)-, (4R,5R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:216805 CAPLUS

DOCUMENT NUMBER: 142:298096

TITLE: Preparation of carbamoylisoxazoles as caspase
inhibitors

INVENTOR(S): Chang, Hye-Kyung; Oh, Yeong-Koo; Park, Cheol-Won;
Jang, Yong-Jin; Park, Tae-Kyo; Kim, Sung-Sub; Kim,
Min-Jung; Park, Mi-Jeong; Park, Jung-Gyu; Park,
Hee-Dong; Min, Kyeong-sik; Lee, Tae-soo; Lee,
Sang-kyun; Kim, Soo-hyeon; Jeong, Hee-kyung; Lee,
Sun-hwa; Kim, Hwa-dong; Kim, Ae-ri; Park, Ki-sook;
Shin, Hyun-ik; Choi, Hyeong-wook; Lee, Kyu-woong; Lee,
Jae-hoon; Heo, Tae-ho; Kim, Ho-jun; Kwon, Tae-sik

PATENT ASSIGNEE(S): Lg Life Sciences Ltd., S. Korea

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021516	A1	20050310	WO 2004-KR2139	20040826

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004268895	A1	20050310	AU 2004-268895	20040826
CA 2535711	A1	20050310	CA 2004-2535711	20040826
EP 1660464	A1	20060531	EP 2004-774400	20040826

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

TR 200600899	T2	20060921	TR 2006-899	20040826
CN 1842521	A	20061004	CN 2004-80024702	20040826
BR 2004013848	A	20061024	BR 2004-13848	20040826
JP 2007503429	T	20070222	JP 2006-524573	20040826
US 20060223848	A1	20061005	US 2006-568503	20060216
IN 2006CN00641	A	20070608	IN 2006-CN641	20060222
MX 2006PA02267	A	20060517	MX 2006-PA2267	20060224
NO 2006001362	A	20060324	NO 2006-1362	20060324

PRIORITY APPLN. INFO.:

KR 2003-59451	A	20030827
WO 2004-KR2139	W	20040826

OTHER SOURCE(S): CASREACT 142:298096; MARPAT 142:298096


IT 847945-47-5P 847945-93-1P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of carbamoylisoxazoles as caspase inhibitors)

RN 847945-47-5 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-93-1 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 847944-97-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of carbamoylisoxazoles as caspase inhibitors)

RN 847944-97-2 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-isoquinolinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



IT 847944-93-8P 847944-94-9P 847944-95-0P
847944-96-1P 847944-98-3P 847944-99-4P
847945-00-0P 847945-01-1P 847945-02-2P
847945-03-3P 847945-04-4P 847945-05-5P
847945-06-6P 847945-07-7P 847945-08-8P
847945-09-9P 847945-10-2P 847945-11-3P
847945-12-4P 847945-13-5P 847945-14-6P
847945-15-7P 847945-16-8P 847945-17-9P
847945-18-0P 847945-19-1P 847945-20-4P
847945-21-5P 847945-22-6P 847945-23-7P
847945-24-8P 847945-25-9P 847945-26-0P
847945-27-1P 847945-28-2P 847945-29-3P
847945-30-6P 847945-31-7P 847945-32-8P
847945-33-9P 847945-34-0P 847945-35-1P
847945-36-2P 847945-37-3P 847945-38-4P
847945-39-5P 847945-40-8P 847945-42-0P
847945-44-2P 847945-45-3P 847945-46-4P
847945-59-9P 847945-94-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carbamoylisoxazoles as caspase inhibitors)

RN 847944-93-8 CAPLUS

CN Pentanoic acid, 3-[[[(5-ethyl-4,5-dihydro-3-phenyl-5-isoxazolyl)carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 847944-94-9 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-naphthalenyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 847944-95-0 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-5-ethyl-4,5-dihydro-3-(2-naphthalenyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 847944-96-1 CAPLUS


CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-isoquinolinyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847944-98-3 CAPLUS


CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-isoquinolinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, ethyl ester (CA INDEX NAME)



RN 847944-99-4 CAPLUS


CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 847945-00-0 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(4-quinolinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 847945-01-1 CAPLUS


CN Pentanoic acid, 3-[[[3-benzo[b]thien-2-yl-5-ethyl-4,5-dihydro-5-isoxazolyl)carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 847945-02-2 CAPLUS


CN Pentanoic acid, 3-[[[3-(1,3-dimethyl-1H-indol-2-yl)-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847945-03-3 CAPLUS


CN Pentanoic acid, 3-[[[3-(1,3-dimethyl-1H-indol-2-yl)-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 847945-04-4 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-naphthalenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-05-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[5-ethyl-4,5-dihydro-3-[2-(1-naphthalenyl)ethyl]-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-06-6 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-[(1-naphthalenyloxy)methyl]-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-07-7 CAPLUS


CN Pentanoic acid, 3-[[[3-[[[4-chloro-1-naphthalenyl]oxy]methyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 847945-08-8 CAPLUS
 CN 2-Hexenedioic acid, 4-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-, 1-ethyl ester, (2E,4S)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 847945-09-9 CAPLUS
 CN 4-Pentenoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-(methylsulfonyl)-, (3S,4E)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 847945-10-2 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-(1-isoquinolinyl)-5-propyl-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-11-3 CAPLUS


CN Pentanoic acid, 3-[[[(5S)-5-ethyl-4,5-dihydro-3-(1-naphthalenyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 847945-12-4 CAPLUS
 CN Pentanoic acid, 3-[[[(5S)-5-ethyl-4,5-dihydro-3-(2-quinolinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 847945-13-5 CAPLUS
 CN Pentanoic acid, 3-[[[(5R)-5-ethyl-4,5-dihydro-3-(3-isoquinolinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-14-6 CAPLUS
 CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(8-quinolinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 847945-15-7 CAPLUS
 CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(3-quinolinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 847945-16-8 CAPLUS
 CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-5-(1-methylethyl)-3-(2-quinolinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-17-9 CAPLUS
 CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-[2-(1-methylethyl)phenyl]-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 847945-18-0 CAPLUS
 CN Pentanoic acid, 3-[[[3-[3-(1,1-dimethylethyl)phenyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 847945-19-1 CAPLUS


CN Pentanoic acid, 3-[[[3-[4-(1,1-dimethylethyl)phenyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 847945-20-4 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-5-(1-methylethyl)-3-[2-(1-methylethyl)phenyl]-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-21-5 CAPLUS


CN Pentanoic acid, 3-[[[(5R)-3-[3-(1,1-dimethylethyl)phenyl]-4,5-dihydro-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 847945-22-6 CAPLUS

CN Pentanoic acid, 3-[[[3-[1,1'-biphenyl]-3-yl]-4,5-dihydro-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 847945-23-7 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(2-pyridinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 847945-24-8 CAPLUS

CN Pentanoic acid, 3-[[[3-[4-(1,1-dimethylethyl)-2-pyridinyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 847945-25-9 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(2-pyridinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-


(CA INDEX NAME)

Absolute stereochemistry.




RN 847945-26-0 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-[4-(2-methylpropyl)-2-pyridinyl]-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 847945-27-1 CAPLUS

CN Pentanoic acid, 3-[[[3-(4-acetyl-2-pyridinyl)-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 847945-28-2 CAPLUS

CN Pentanoic acid, 3-[[[3-(4-cyclopropyl-2-pyridinyl)-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 847945-29-3 CAPLUS
 CN Pentanoic acid, 3-[[[3-(4-cyclopentyl-2-pyridinyl)-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 847945-30-6 CAPLUS
 CN Pentanoic acid, 3-[[[(5R)-3-(4-cyclopentyl-2-pyridinyl)-4,5-dihydro-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-31-7 CAPLUS
 CN Pentanoic acid, 3-[[[3-(4-cyclohexyl-2-pyridinyl)-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)




RN 847945-32-8 CAPLUS
 CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(5,6,7,8-tetrahydro-1-isoquinolinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 847945-33-9 CAPLUS


CN Pentanoic acid, 3-[[[4,5-dihydro-5-(1-methylethyl)-3-(4-phenyl-2-pyridinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 847945-34-0 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-[(diphenylphosphinyl)oxy]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-35-1 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-36-2 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-[[2,5-dihydro-5-oxo-4-(phenylmethyl)-3-furanyl]oxy]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-37-3 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-(2-methyl-1-oxopropoxy)-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-38-4 CAPLUS

CN 5-Hexenoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-39-5 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2-pyridinyloxy)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-40-8 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-[2-(1-methylethyl)phenyl]-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2-pyridinyloxy)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847945-42-0 CAPLUS


CN Pyridinium, 2-[(3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutoxy]-1-methyl-, 1,1,1-trifluoromethanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 847945-41-9

CMF C27 H29 N4 O6


Absolute stereochemistry.



CM 2

CRN 37181-39-8

CMF C F3 O3 S



RN 847945-44-2 CAPLUS


CN Pyridinium, 2-[(3S)-4-carboxy-3-[[[5-ethyl-4,5-dihydro-3-[2-(1-methylethyl)phenyl]-5-isoxazolyl]carbonyl]amino]-2-oxobutoxy]-1-methyl-, 1,1,1-trifluoromethanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 847945-43-1

CMF C26 H32 N3 O6


Absolute stereochemistry.



CM 2


CRN 37181-39-8

CMF C F3 O3 S




RN 847945-45-3 CAPLUS

CN Pentanoic acid, 3-[[[3-(5-chloro-1-methyl-1H-indol-2-yl)-4,5-dihydro-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 847945-46-4 CAPLUS


CN Pentanoic acid, 3-[[[3-(1,5-dimethyl-1H-indol-2-yl)-4,5-dihydro-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)



RN 847945-59-9 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-5-ethyl-4,5-dihydro-3-(2-naphthalenyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-94-2 CAPLUS


CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.




IT 847945-91-9P 847945-92-0P
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of carbamoylisoxazoles as caspase inhibitors)
 RN 847945-91-9 CAPLUS
 CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinylyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 847945-92-0 CAPLUS
 CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinylyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 935248-12-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of carbamoylisoxazoles as caspase inhibitors)
 RN 935248-12-7 CAPLUS
 CN L-Aspartic acid, N-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.



IT 847945-50-0P 847945-51-1P 847945-52-2P
 847945-54-4P 847945-56-6P 847945-58-8P
 847945-61-3P 847945-62-4P 847945-64-6P
 847945-66-8P 847945-68-0P 847945-71-5P
 847945-72-6P 847945-74-8P 847945-75-9P
 847945-80-6P 847945-81-7P 847945-82-8P
 847945-83-9P 847945-88-4P 847945-95-3P
 847945-96-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of carbamoylisoxazoles as caspase inhibitors)
 RN 847945-50-0 CAPLUS
 CN D-glycero-Pentonic acid, 2,3-dideoxy-3-[[[(4,5-dihydro-5-methyl-3-phenyl-5-isoxazolyl)carbonyl]amino]-, 1,1-dimethylethyl ester, 5-(2,6-dichlorobenzoate), (4ξ)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-51-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(4,5-dihydro-5-methyl-3-phenyl-5-isoxazolyl)carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-52-2 CAPLUS

CN D-glycero-Pentonic acid, 2,3-dideoxy-3-[[[(4,5-dihydro-5-methyl-3-phenyl-5-isoxazolyl)carbonyl]amino]-5-O-phenyl-, 1,1-dimethylethyl ester, (4ξ)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-54-4 CAPLUS

CN Pentanoic acid, 3-[[[(5-ethyl-4,5-dihydro-3-phenyl-5-isoxazolyl)carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-56-6 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-naphthalenyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-58-8 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(2-naphthalenyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 847945-61-3 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-isoquinolinyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847945-62-4 CAPLUS


CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-isoquinolinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847945-64-6 CAPLUS


CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 847945-66-8 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(4-quinolinyl)-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847945-68-0 CAPLUS


CN Pentanoic acid, 3-[[[3-benzo[b]thien-2-yl-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847945-71-5 CAPLUS


CN Pentanoic acid, 3-[[[3-(1,3-dimethyl-1H-indol-2-yl)-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 847945-72-6 CAPLUS


CN Pentanoic acid, 3-[[[3-(1,3-dimethyl-1H-indol-2-yl)-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-5-fluoro-4-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 847945-74-8 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-(1-naphthalenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-75-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-5-(1,1-dimethylethoxy)-3-[[[5-ethyl-4,5-dihydro-3-[2-(1-naphthalenyl)ethyl]-5-isoxazolyl]carbonyl]amino]-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-80-6 CAPLUS

CN Butanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-4-hydroxy-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 847945-81-7 CAPLUS

CN 2-Hexenedioic acid, 4-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-, 6-(1,1-dimethylethyl) 1-ethyl ester, (2E,4S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 847945-82-8 CAPLUS

CN 4-Pentenoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinylnyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-5-(methylsulfonyl)-, 1,1-dimethylethyl ester, (3S,4E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 847945-83-9 CAPLUS

CN Butanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinylnyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-88-4 CAPLUS

CN Pentanoic acid, 3-[[[5-ethyl-4,5-dihydro-3-[2-(1-methylethyl)phenyl]-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2-pyridinyloxy)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-95-3 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-5-methyl-3-phenyl-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847945-96-4 CAPLUS


CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-(1-isoquinolinyl)-5-(1-methylethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(2-pyridinyloxy)-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 847944-91-6P 847944-92-7P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of carbamoylisoxazoles as caspase inhibitors)
 RN 847944-91-6 CAPLUS
 CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[4,5-dihydro-5-methyl-3-phenyl-5-isoxazolyl)carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 847944-92-7 CAPLUS
 CN Pentanoic acid, 3-[[4,5-dihydro-5-methyl-3-phenyl-5-isoxazolyl)carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:228870 CAPLUS
 DOCUMENT NUMBER: 134:262851
 TITLE: Isoxazoline derivative caspase inhibitors for

pharmaceutical uses

INVENTOR(S) : Kim, Eunice Eun-Kyeong; Park, Mi-Jeong; Lee, Tae-Hee;
 Chang, Hye-Kyung; Park, Tae-Kyo; Kang, Chang-Yuil;
 Kim, Young-Myeong; Moon, Kwang-Yul; Oh, Young-Leem;
 Min, Chang-Hee; Chung, Hyun Ho

PATENT ASSIGNEE(S) : LG Chemical Ltd., S. Korea

SOURCE: PCT Int. Appl., 168 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021600	A1	20010329	WO 2000-KR1047	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001021599	A1	20010329	WO 1999-KR561	19990917
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
KR 2001045347	A	20010605	KR 1999-48608	19991104
CA 2388564	A1	20010329	CA 2000-2388564	20000918
CA 2388564	C	20071106		
AU 2000073223	A	20010424	AU 2000-73223	20000918
EP 1212309	A1	20020612	EP 2000-961242	20000918
EP 1212309	B1	20040818		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509502	T	20030311	JP 2001-524979	20000918
AT 273705	T	20040915	AT 2000-961242	20000918
US 6747050	B1	20040608	US 2002-88288	20020315
PRIORITY APPLN. INFO.:				
			WO 1999-KR561	A 19990917
			KR 1999-48608	A 19991104
			KR 1999-561	A 19990917
			WO 2000-KR1047	W 20000918

OTHER SOURCE(S) : MARPAT 134:262851

IT 331778-32-6P 331778-33-7P 331778-36-0P
 331778-37-1P 331778-38-2P 331778-39-3P
 331778-40-6P 331778-42-8P 331778-43-9P
 331778-44-0P 331778-45-1P 331778-46-2P
 331778-47-3P 331778-48-4P 331778-50-8P
 331778-51-9P 331778-52-0P 331778-55-3P
 331778-60-0P 331778-61-1P 331778-62-2P
 331778-63-3P 331778-64-4P 331778-66-6P
 331778-67-7P 331778-76-8P 331778-77-9P
 331778-80-4P 331778-86-0P 331778-88-2P
 331778-90-6P 332020-42-5P 332020-44-7P
 332020-48-1P 332020-52-7P 332020-61-8P

332020-64-1P 332020-66-3P 332020-67-4P
 332020-68-5P 332020-70-9P 332020-72-1P
 332020-74-3P 332020-76-5P 332020-78-7P
 332020-80-1P 332020-82-3P 332020-84-5P
 332020-86-7P 332020-88-9P 332020-90-3P
 332020-92-5P 332020-94-7P 332020-95-8P
 332020-97-0P 332020-99-2P 332021-01-9P
 332021-03-1P 332021-05-3P 332021-07-5P
 332021-09-7P 332021-11-1P 332021-13-3P
 332021-15-5P 332021-17-7P 332021-19-9P
 332021-21-3P 332021-23-5P 332021-25-7P
 332021-27-9P 332021-29-1P 332021-32-6P
 332021-34-8P 332021-36-0P 332021-38-2P
 332021-40-6P 332021-43-9P 332021-44-0P
 332021-46-2P 332021-48-4P 332021-50-8P
 332021-52-0P 332022-99-8P 332023-01-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(isoxazoline derivative caspase inhibitors for pharmaceutical uses)

RN 331778-32-6 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-33-7 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-36-0 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-37-1 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-38-2 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-39-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-40-6 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-42-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-43-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-44-0 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-45-1 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(2-naphthalenyloxy)-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-46-2 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(2-naphthalenyloxy)-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-47-3 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(2-naphthalenyloxy)-4-oxo-, methyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-48-4 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(1-naphthalenyloxy)-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-50-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-oxo-3-phenylpropyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-51-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-52-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-55-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(phenylmethyl)sulfonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-60-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-61-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-62-2 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-63-3 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-64-4 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-5-(1H-imidazol-1-ylmethyl)-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-66-6 CAPLUS

CN Pentanoic acid, 3-[[[3-[[[1S]-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-67-7 CAPLUS

CN 1-Piperidinepentanoic acid, β -[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]- γ -oxo-, (β S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-76-8 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylsulfonyl)amino]propyl]-5-(phenoxy-methyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)

isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-77-9 CAPLUS

CN 3-Isoxazolebutanoic acid, γ -[[[(2S)-2-(acetylamino)-3-carboxy-1-oxopropyl]amino]-5-[[[(1S)-1-(carboxymethyl)-2-oxo-3-phenoxypropyl]amino]carbonyl]-4,5-dihydro-5-methyl-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-80-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-86-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylsulfonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-88-2 CAPLUS


CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-1-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



RN 331778-90-6 CAPLUS


CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-1-[[2-(1H-indol-3-yl)acetyl]amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 332020-42-5 CAPLUS
 CN Butanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-
 [[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-
 isoxazolyl]carbonyl]amino]-4-(methoxymethylamino)-4-oxo-, methyl ester,
 (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 332020-44-7 CAPLUS
 CN Butanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-
 [[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-
 isoxazolyl]carbonyl]amino]-4-(methoxymethylamino)-4-oxo-, methyl ester,
 (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-48-1 CAPLUS

CN 3-Isoxazolebutanoic acid, 5-[[[(1S)-1-(carboxymethyl)-2-oxo-3-phenoxypentyl]amino]carbonyl]-4,5-dihydro-5-methyl-γ-[(2-naphthalenylcarbonyl)amino]-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-52-7 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-61-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-1-[[3-(4-hydroxyphenyl)-1-oxopropyl]amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-64-1 CAPLUS

CN 3-Isoxazolebutanoic acid, 5-[[[(1S)-1-(carboxymethyl)-2-oxo-3-phenoxypropyl]amino]carbonyl]-γ-[(3-carboxy-1-oxopropyl)amino]-4,5-dihydro-5-methyl-, (γS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-66-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-1-[(1-isoquinolinylcarbonyl)amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 332020-67-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-1-[(1-isoquinolinylcarbonyl)amino]-2-methylpropyl]-5-(phenylmethyl)-5-

isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-68-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-1-[(3-isoquinolinylcarbonyl)amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-70-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-1-[(3-isoquinolinylcarbonyl)amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-72-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(4-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-74-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(4-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-76-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-3-[(1S)-1-[(2-benzofuranylcarbonyl)amino]-2-methylpropyl]-4,5-dihydro-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 332020-78-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-3-[(1S)-1-[(2-

benzofuranylcarbonyl)amino]-2-methylpropyl]-4,5-dihydro-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-80-1 CAPLUS

CN Benzoic acid, 2,6-difluoro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-82-3 CAPLUS


CN Benzoic acid, 2,6-difluoro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 332020-84-5 CAPLUS


Absolute stereochemistry.




Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.



RN 332020-92-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-1-[(1H-indol-2-ylcarbonyl)amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-94-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-1-[(1H-indol-2-ylcarbonyl)amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-95-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-1-[(1H-indol-3-ylcarbonyl)amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-97-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-1-[(1H-indol-3-ylcarbonyl)amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332020-99-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-5-methyl-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-01-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-5-methyl-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-03-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-3-[(1S)-1-[(2-benzofuranylcarbonyl)amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-05-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-3-[(1S)-1-[(2-benzofuranylcarbonyl)amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-07-5 CAPLUS

CN 3-Isoxazolebutanoic acid, 5-[[[(1S)-1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]amino]carbonyl]-γ-[(3-carboxy-1-oxopropyl)amino]-4,5-dihydro-5-methyl-, (γS,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-09-7 CAPLUS

CN 3-Isoxazolebutanoic acid, 5-[[[(1S)-1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]amino]carbonyl]-γ-[(3-carboxy-1-oxopropyl)amino]-4,5-dihydro-5-methyl-, (γS,5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-11-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 332021-13-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-3-[(1S)-1-[(3-

carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-15-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-propyl-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-17-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-propyl-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-19-9 CAPLUS

CN Pentanoic acid, 3-[[[3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(1-piperidinylmethoxy)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-21-3 CAPLUS

CN Pentanoic acid, 3-[[[3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-4-oxo-5-(1-pyrrolidinylmethoxy)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-23-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-5-butyl-3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-25-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-5-butyl-3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-4-carboxy-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-27-9 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-5-(2-naphthalenyloxy)-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-29-1 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-5-(2-naphthalenyloxy)-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-32-6 CAPLUS

CN Pentanoic acid, 3-[[[3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-propyl-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-34-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-(hydroxymethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-36-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-38-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-40-6 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-(methoxymethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-43-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-pentyl-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-44-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-pentyl-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 332021-46-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-3-[(1S)-1-[(3-

carboxy-1-oxopropyl)amino]-2-methylpropyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-48-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-50-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-3-[(1S)-1-[(4-carboxy-1-oxobutyl)amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332021-52-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-3-[(1S)-1-[(4-carboxy-1-oxobutyl)amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 332022-99-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-oxo-3-phenyl-2-propen-1-yl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 332023-01-5 CAPLUS


CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-oxo-3-phenyl-2-propen-1-yl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 331777-90-3 331777-91-4 331779-28-3
332022-85-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(isoxazoline derivative caspase inhibitors for pharmaceutical uses)
RN 331777-90-3 CAPLUS
CN Butanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-(methoxymethylamino)-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 331777-91-4 CAPLUS
CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331779-28-3 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethoxy)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332022-85-2 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 331777-89-0P 331777-92-5P 331777-93-6P
 331777-94-7P 331777-96-9P 331777-97-0P
 331777-98-1P 331777-99-2P 331778-00-8P
 331778-01-9P 331778-03-1P 331778-04-2P
 331778-05-3P 331778-06-4P 331778-07-5P

331778-09-7P 331778-10-0P 331778-11-1P
 331778-12-2P 331778-13-3P 331778-14-4P
 331778-23-5P 331778-24-6P 331778-26-8P
 331778-27-9P 331778-28-0P 331778-29-1P
 332022-48-7P 332022-58-9P 332022-60-3P
 332022-63-6P 332022-72-7P 332022-74-9P
 332022-78-3P 332022-80-7P 332022-82-9P
 332022-92-1P 332028-44-1P 332028-45-2P


RL: SPN (Synthetic preparation); PREP (Preparation)

(isoxazoline derivative caspase inhibitors for pharmaceutical uses)

RN 331777-89-0 CAPLUS

CN Butanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-
 [[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-
 isoxazolyl]carbonyl]amino]-4-(methoxymethylamino)-4-oxo-,
 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-92-5 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-
 [[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-
 isoxazolyl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA
 INDEX NAME)

Absolute stereochemistry.




RN 331777-93-6 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-
 naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-

, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-94-7 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-96-9 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-oxo-3-phenylpropyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-97-0 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-98-1 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylsulfonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-99-2 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[[phenylmethoxy]carbonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-00-8 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-1-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-01-9 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-1-[(1H-indol-3-yl)acetyl]amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-03-1 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[[(phenylmethyl)sulfonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-04-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-05-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-06-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 331778-07-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 331778-09-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 331778-10-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-11-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-12-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-13-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 331778-14-4 CAPLUS


CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)

Absolute stereochemistry.




RN 331778-23-5 CAPLUS
 CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-24-6 CAPLUS
 CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 331778-26-8 CAPLUS
 CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-27-9 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-28-0 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(2-naphthalenyloxy)-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-29-1 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-

isoxazolyl]carbonyl]amino]-5-(2-naphthalenyloxy)-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 332022-48-7 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-oxo-3-phenyl-2-propen-1-yl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 332022-58-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-oxo-3-phenyl-2-propen-1-yl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 332022-60-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[[(phenylmethyl)sulfonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332022-63-6 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332022-72-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-5-(1,1-dimethylethoxy)-3-[[[(5R)-3-[(1S)-1-[[4-(1,1-dimethylethoxy)-1,4-dioxobutyl]amino]-2-methylpropyl]-4,5-dihydro-5-pentyl-5-isoxazolyl]carbonyl]amino]-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332022-74-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-5-(1,1-dimethylethoxy)-3-[[[(5S)-3-[(1S)-1-[[4-(1,1-dimethylethoxy)-1,4-dioxobutyl]amino]-2-methylpropyl]-4,5-dihydro-5-pentyl-5-isoxazolyl]carbonyl]amino]-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332022-78-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-5-(1,1-dimethylethoxy)-3-[[[3-[(1S)-1-[[4-(1,1-dimethylethoxy)-1,4-dioxobutyl]amino]-2-methylpropyl]-5-ethyl-4,5-dihydro-5-isoxazolyl]carbonyl]amino]-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332022-80-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-5-(1,1-dimethylethoxy)-3-[[[5R)-3-[(1S)-1-[[4-(1,1-dimethylethoxy)-1,4-dioxobutyl]amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332022-82-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-5-(1,1-dimethylethoxy)-3-[[[(5S)-3-[(1S)-1-[4-(1,1-dimethylethoxy)-1,4-dioxobutyl]amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332022-92-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-oxo-3-phenyl-2-propen-1-yl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 332028-44-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-5-(1,1-dimethylethoxy)-3-[[[(5R)-3-[(1S)-1-[[4-(1,1-dimethylethoxy)-1,4-dioxobutyl]amino]-2-methylpropyl]-4,5-dihydro-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 332028-45-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-5-(1,1-dimethylethoxy)-3-[[[(5S)-3-[(1S)-1-[[4-(1,1-dimethylethoxy)-1,4-dioxobutyl]amino]-2-methylpropyl]-4,5-dihydro-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2,5-dioxopentyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:228869 CAPLUS
 DOCUMENT NUMBER: 134:266298
 TITLE: Preparation of 2-isoxazoline-5-carboxamides as caspase inhibitors
 INVENTOR(S): Park, Tae-Kyo; Chang, Hye-Kyung; Chung, Hyun-Ho; Min, Chang-Hee; Oh, Young-Leem; Park, Mi-Jeong; Lee, Tae-Hee; Moon, Kwang-Yul; Kim, Eunice Eun-Kyeong
 PATENT ASSIGNEE(S): LG Chemical Ltd., S. Korea
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021599	A1	20010329	WO 1999-KR561	19990917
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9957628	A	20010424	AU 1999-57628	19990917
CA 2388564	A1	20010329	CA 2000-2388564	20000918
CA 2388564	C	20071106		
WO 2001021600	A1	20010329	WO 2000-KR1047	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000073223	A	20010424	AU 2000-73223	20000918

EP 1212309	A1	20020612	EP 2000-961242	20000918
EP 1212309	B1	20040818		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 273705	T	20040915	AT 2000-961242	20000918
ZA 2002002148	A	20030317	ZA 2002-2148	20020315
US 6747050	B1	20040608	US 2002-88288	20020315
PRIORITY APPLN. INFO.:			WO 1999-KR561	A 19990917
			KR 1999-48608	A 19991104
			WO 2000-KR1047	W 20000918

OTHER SOURCE(S): MARPAT 134:266298


IT 331778-32-6P 331778-33-7P 331778-36-0P
 331778-37-1P 331778-38-2P 331778-39-3P
 331778-40-6P 331778-41-7P 331778-42-8P
 331778-43-9P 331778-44-0P 331778-45-1P
 331778-46-2P 331778-47-3P 331778-48-4P
 331778-50-8P 331778-51-9P 331778-52-0P
 331778-53-1P 331778-54-2P 331778-55-3P
 331778-60-0P 331778-61-1P 331778-62-2P
 331778-63-3P 331778-64-4P 331778-66-6P
 331778-67-7P 331778-68-8P 331778-69-9P
 331778-71-3P 331778-72-4P 331778-73-5P
 331778-74-6P 331778-75-7P 331778-76-8P
 331778-77-9P 331778-79-1P 331778-80-4P
 331778-81-5P 331778-82-6P 331778-84-8P
 331778-85-9P 331778-86-0P 331778-87-1P
 331778-88-2P 331778-89-3P 331778-90-6P
 331778-91-7P 331778-92-8P 331778-93-9P
 331778-98-4P 331778-99-5P 332113-92-5P
 332113-93-6P 332113-94-7P 332113-95-8P
 332113-96-9P 332113-97-0P 332113-98-1P
 332113-99-2P 332114-00-8P 332114-01-9P
 332114-03-1P 332114-05-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-isoxazoline-5-carboxamides as caspase inhibitors)

RN 331778-32-6 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-33-7 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-

isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-36-0 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-37-1 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-38-2 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-

naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-39-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-40-6 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-41-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-42-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-43-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-44-0 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-45-1 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(2-naphthalenyloxy)-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-46-2 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(2-naphthalenyloxy)-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-47-3 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(2-naphthalenyloxy)-4-oxo-, methyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-48-4 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(1-naphthalenyloxy)-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-50-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-oxo-3-phenylpropyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-51-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-52-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-53-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 331778-54-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 331778-55-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(4S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-60-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-61-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-62-2 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-63-3 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-64-4 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-5-(1H-imidazol-1-ylmethyl)-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-66-6 CAPLUS

CN Pentanoic acid, 3-[[[3-[(1S)-1-[(3-carboxy-1-oxopropyl)amino]-2-methylpropyl]-4,5-dihydro-5-methyl-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-67-7 CAPLUS

CN 1-Piperidinepentanoic acid, β -[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]- γ -oxo-, (β S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-68-8 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-69-9 CAPLUS


CN Butanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-(methoxymethylamino)-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-71-3 CAPLUS
 CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-72-4 CAPLUS
 CN Pentanoic acid, 5-bromo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-73-5 CAPLUS
 CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 331778-74-6 CAPLUS
 CN Pentanoic acid, 5-bromo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-75-7 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-5-methyl-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-76-8 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylsulfonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-77-9 CAPLUS

CN 3-Isoxazolebutanoic acid, γ -[[[(2S)-2-(acetylamino)-3-carboxy-1-oxopropyl]amino]-5-[[[(1S)-1-(carboxymethyl)-2-oxo-3-phenoxypropyl]amino]carbonyl]-4,5-dihydro-5-methyl-, (γ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-79-1 CAPLUS

CN Pentanoic acid, 5-bromo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-80-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-81-5 CAPLUS

CN Pentanoic acid, 5-bromo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-oxo-3-phenylpropyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-82-6 CAPLUS

CN Pentanoic acid, 5-bromo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-84-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-85-9 CAPLUS

CN Pentanoic acid, 5-bromo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylsulfonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-86-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylsulfonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-87-1 CAPLUS

CN Pentanoic acid, 5-bromo-3-[[[4,5-dihydro-3-[(1S)-1-[[3-(1H-indol-3-yl)-1-

oxopropyl]amino]-2-methylpropyl]-5-(phenylmethyl)-5-
isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-88-2 CAPLUS


CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-1-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



RN 331778-89-3 CAPLUS

CN Pentanoic acid, 5-bromo-3-[[[4,5-dihydro-3-[(1S)-1-[[2-(1H-indol-3-yl)acetyl]amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-90-6 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-1-[[2-(1H-indol-3-yl)acetyl]amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-91-7 CAPLUS

CN Pentanoic acid, 5-bromo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 331778-92-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]propyl]-5-

(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 331778-93-9 CAPLUS

CN Pentanoic acid, 5-bromo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethyl)sulfonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-98-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-99-5 CAPLUS

CN Pentanoic acid, 3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332113-92-5 CAPLUS

CN Pentanoic acid, 5-diazo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332113-93-6 CAPLUS

CN Pentanoic acid, 5-diazo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332113-94-7 CAPLUS

CN Pentanoic acid, 5-diazo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332113-95-8 CAPLUS

CN Pentanoic acid, 5-diazo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-oxo-3-phenylpropyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332113-96-9 CAPLUS

CN Pentanoic acid, 5-diazo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332113-97-0 CAPLUS

CN Pentanoic acid, 5-diazo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylsulfonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332113-98-1 CAPLUS

CN Pentanoic acid, 5-diazo-3-[[[4,5-dihydro-3-[(1S)-1-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332113-99-2 CAPLUS

CN Pentanoic acid, 5-diazo-3-[[[4,5-dihydro-3-[(1S)-1-[[2-(1H-indol-3-yl)acetyl]amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332114-00-8 CAPLUS

CN Pentanoic acid, 5-diazo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 332114-01-9 CAPLUS

CN Pentanoic acid, 5-diazo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethyl)sulfonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 332114-03-1 CAPLUS


CN Pentanoic acid, 5-diazo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 332114-05-3 CAPLUS
 CN Pentanoic acid, 5-bromo-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 331779-28-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 2-isoxazoline-5-carboxamides as caspase inhibitors)
 RN 331779-28-3 CAPLUS
 CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.



IT 331777-89-0P 331777-90-3P 331777-91-4P
 331777-92-5P 331777-93-6P 331777-94-7P
 331777-96-9P 331777-97-0P 331777-98-1P
 331777-99-2P 331778-00-8P 331778-01-9P
 331778-02-0P 331778-03-1P 331778-04-2P
 331778-05-3P 331778-06-4P 331778-07-5P
 331778-09-7P 331778-10-0P 331778-11-1P
 331778-12-2P 331778-13-3P 331778-14-4P
 331778-15-5P 331778-16-6P 331778-17-7P
 331778-18-8P 331778-21-3P 331778-22-4P
 331778-23-5P 331778-24-6P 331778-26-8P
 331778-27-9P 331778-28-0P 331778-29-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 2-isoxazoline-5-carboxamides as caspase inhibitors)
 RN 331777-89-0 CAPLUS
 CN Butanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxyethyl)-5-isoxazolyl]carbonyl]amino]-4-(methoxymethylamino)-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-90-3 CAPLUS

CN Butanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxy)methyl)-5-isoxazolyl]carbonyl]amino]-4-(methoxymethylamino)-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-91-4 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxy)methyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-92-5 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenoxyethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-93-6 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 331777-94-7 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxyethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 331777-96-9 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-oxo-3-phenylpropyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-97-0 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-98-1 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylsulfonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331777-99-2 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[[[(phenylmethoxy)carbonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-00-8 CAPLUS

CN L-Aspartic acid, N-[[[4,5-dihydro-3-[(1S)-1-[[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-01-9 CAPLUS

CN L-Aspartic acid, N-[[4,5-dihydro-3-[(1S)-1-[(1H-indol-3-ylacetyl)amino]-2-methylpropyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-02-0 CAPLUS

CN L-Aspartic acid, N-[[4,5-dihydro-3-[(1S)-2-methyl-1-[[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 331778-03-1 CAPLUS

CN L-Aspartic acid, N-[[4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethyl)sulfonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]-, 4-(1,1-dimethylethyl) 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-04-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-05-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-06-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 331778-07-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 331778-09-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 331778-10-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-11-1 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phoxymethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-12-2 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phoxymethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-13-3 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 331778-14-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 331778-15-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 331778-16-6 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 331778-17-7 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[[(phenylmethyl)sulfonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 331778-18-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(phenylmethyl)sulfonyl]amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)


Absolute stereochemistry.



RN 331778-21-3 CAPLUS


CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
(CA INDEX NAME)

Absolute stereochemistry.




RN 331778-22-4 CAPLUS
 CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester
 (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-23-5 CAPLUS
 CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 331778-24-6 CAPLUS
 CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-quinolinylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-26-8 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-27-9 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-4-oxo-5-phenoxy-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 331778-28-0 CAPLUS

CN Pentanoic acid, 3-[[[(5S)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-

isoxazolyl]carbonyl]amino]-5-(2-naphthalenyloxy)-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 331778-29-1 CAPLUS

CN Pentanoic acid, 3-[[[(5R)-4,5-dihydro-3-[(1S)-2-methyl-1-[(2-naphthalenylcarbonyl)amino]propyl]-5-(phenoxymethyl)-5-isoxazolyl]carbonyl]amino]-5-(2-naphthalenyloxy)-4-oxo-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:48625 CAPLUS

DOCUMENT NUMBER: 135:71005

TITLE: A broad-spectrum caspase inhibitor blocks concanavalin a-induced hepatitis in mice

AUTHOR(S): Kim, Kwang-Mi; Kim, Young-Myeong; Park, MiJeong; Park, Kiwon; Chang, Hye Kyung; Park, Tae Kyo; Chung, Hyun-Ho; Kang, Chang-Yuil

CORPORATE SOURCE: Laboratory of Immunology, College of Pharmacy, Seoul National University, Seoul, 151-742, S. Korea

SOURCE: Clinical Immunology (Orlando, Florida) (2000), 97(3), 221-233

CODEN: CLIIFY; ISSN: 1521-6616

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 331778-84-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(broad-spectrum caspase inhibitor blocks Con A-induced hepatitis in mice)

RN 331778-84-8 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[4,5-dihydro-3-[(1S)-2-methyl-1-[(1-naphthalenylcarbonyl)amino]propyl]-5-(phenylmethyl)-5-isoxazolyl]carbonyl]amino]-2-oxobutyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:623742 CAPLUS

DOCUMENT NUMBER: 133:222722

TITLE: Preparation of isoxazoline compounds as inhibitors of TNF release

INVENTOR(S): Cohan, Victoria Lee; Kleinman, Edward Fox

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S., 19 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6114367	A	20000905	US 1998-187833	19981106
			US 1998-187833	19981106

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 133:222722

IT 167099-17-4P 167099-18-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of isoxazolines as inhibitors of TNF release)

RN 167099-17-4 CAPLUS

CN 5-Isioxazolecarboxamide, 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydro-5-methyl-N-[(1S)-1-phenylethyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 167099-18-5 CAPLUS

CN 5-Isioxazolecarboxamide, 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydro-5-methyl-N-[(1S)-1-phenylethyl]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:118606 CAPLUS

DOCUMENT NUMBER: 128:180405

ORIGINAL REFERENCE NO.: 128:35606h,35607a

TITLE: Preparation of isoxazolines as antiinflammatory agents

INVENTOR(S): Kleinman, Edward Fox

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S., 15 pp., Cont.-in-part of U.S. Ser. No. 262,086, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5716967	A	19980210	US 1996-640944	19960515
WO 9514681	A1	19950601	WO 1994-IB333	19941026
W: AU, BR, CA, CN, CZ, HU, JP, KR, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9409379	A	19960527	ZA 1994-9379	19941125
PRIORITY APPLN. INFO.:			US 1993-157248	B2 19931126
			US 1994-262086	B2 19940617
			WO 1994-IB333	W 19941026

OTHER SOURCE(S): MARPAT 128:180405

IT 167099-17-4P 167099-18-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(preparation of isoxazolines as antiinflammatory agents)

RN 167099-17-4 CAPLUS

CN 5-Isioxazolecarboxamide, 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydro-5-methyl-N-[(1S)-1-phenylethyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 167099-18-5 CAPLUS

CN 5-Isioxazolecarboxamide, 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydro-5-methyl-N-[(1S)-1-phenylethyl]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:43032 CAPLUS

DOCUMENT NUMBER: 128:188289

ORIGINAL REFERENCE NO.: 128:37045a,37048a

TITLE: Striking Effect of Hydroxamic Acid Substitution on the Phosphodiesterase Type 4 (PDE4) and TNF α

Inhibitory Activity of Two Series of Rolipram Analogs: Implications for a New Active Site Model of PDE4

AUTHOR(S): Kleinman, Edward F.; Campbell, Erin; Giordano, Lisa A.; Cohan, Victoria L.; Jenkinson, Teresa H.; Cheng, John B.; Shirley, John T.; Pettipher, E. Roy; Salter, Eben D.; Hibbs, Tessa A.; DiCapua, Frank M.; Bordner, John

CORPORATE SOURCE: Central Research Division, Pfizer Inc, Groton, CT, 06340, USA

SOURCE: Journal of Medicinal Chemistry (1998), 41(3), 266-270
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 167099-17-4P 167099-18-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and structure activity relations of hydroxamic acid analogs as
inhibitors of phosphodiesterase type 4 and TNF- α)

RN 167099-17-4 CAPLUS

CN 5-Isioxazolecarboxamide, 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydro-
5-methyl-N-[(1S)-1-phenylethyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 167099-18-5 CAPLUS

CN 5-Isioxazolecarboxamide, 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydro-
5-methyl-N-[(1S)-1-phenylethyl]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:503386 CAPLUS

DOCUMENT NUMBER: 127:135788

ORIGINAL REFERENCE NO.: 127:26197a, 26200a

TITLE: Preparation of isoxazoline, isothiazoline and
pyrazoline as factor Xa inhibitors

INVENTOR(S): Quan, Mimi Lifan; Wityak, John; Galemme, Robert
Anthony, Jr.; Stouten, Petrus F. W.; Pruitt, James
Russell

PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Company, USA

SOURCE: PCT Int. Appl., 191 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9723212	A1	19970703	WO 1996-US20076	19961217
W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT,				


LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 CA 2240946 A1 19970703 CA 1996-2240946 19961217
 CA 2240946 C 20020910
 AU 9713358 A 19970717 AU 1997-13358 19961217
 EP 874629 A1 19981104 EP 1996-944844 19961217
 EP 874629 B1 20040519
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
 US 5939418 A 19990817 US 1996-768908 19961217
 JP 2001502655 T 20010227 JP 1997-523762 19961217
 AT 267011 T 20040615 AT 1996-944844 19961217
 ES 2219706 T3 20041201 ES 1996-944844 19961217
 ZA 9610704 A 19980619 ZA 1996-10704 19961219
 PRIORITY APPLN. INFO.: US 1995-9508P P 19951221
 US 1996-646903 A 19960508
 US 1996-30666P P 19961112
 WO 1996-US20076 W 19961217
 OTHER SOURCE(S): MARPAT 127:135788
 IT 193004-01-2P 193004-39-6P 193004-48-7P
 193004-71-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of isoxazoline, isothiazoline and pyrazoline as factor Xa
 inhibitors)
 RN 193004-01-2 CAPLUS
 CN 5-Isoxazoleacetic acid, 3-[3-(aminoiminomethyl)phenyl]-5-[[[2'-(
 aminosulfonyl)[1,1'-biphenyl]-4-yl]methyl]amino]carbonyl]-4,5-dihydro-,
 methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)
 CM 1
 CRN 193004-00-1
 CMF C27 H27 N5 O6 S




CRN 76-05-1
CMF C2 H F3 O2



RN 193004-39-6 CAPLUS
CN 5-Isioxazoleacetic acid, 3-[3-(aminoiminomethyl)phenyl]-5-[[[4-(aminosulfonyl)phenyl)methyl]amino]carbonyl]-4,5-dihydro-, methyl ester
(CA INDEX NAME)




RN 193004-48-7 CAPLUS
CN 5-Isioxazoleacetamide, 3-[3-(aminoiminomethyl)phenyl]-5-[[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl)methyl]amino]carbonyl]-4,5-dihydro-
(CA INDEX NAME)



RN 193004-71-6 CAPLUS

CN 5-Isioxazoleacetic acid, 3-[3-(aminoiminomethyl)phenyl]-4,5-dihydro-5-[[[2-(1H-imidazol-5-yl)ethyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)




IT 193006-37-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of isoxazoline, isothiazoline and pyrazoline as factor Xa inhibitors)

RN 193006-37-0 CAPLUS

CN 5-Isioxazoleacetic acid, 3-(3-cyanophenyl)-5-[[[2'-[[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]amino]carbonyl]-4,5-dihydro-, methyl ester (CA INDEX NAME)




L12 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:994847 CAPLUS
 DOCUMENT NUMBER: 124:117297
 ORIGINAL REFERENCE NO.: 124:21849a
 TITLE: Isoxazoline compounds as inhibitors of TNF release
 INVENTOR(S): Cohan, Victoria L.; Kleinman, Edward F.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9524398	A1	19950914	WO 1995-IB78	19950203
W: AU, CA, CN, FI, JP, KR, MX, NO, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9514647	A	19950925	AU 1995-14647	19950203
AU 684887	B2	19980108		
EP 749428	A1	19961227	EP 1995-906459	19950203
EP 749428	B1	19980729		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1143363	A	19970219	CN 1995-192000	19950203
JP 09505082	T	19970520	JP 1995-523329	19950203
AT 169009	T	19980815	AT 1995-906459	19950203
ES 2118557	T3	19980916	ES 1995-906459	19950203
CA 2185019	C	20000808	CA 1995-2185019	19950203
NZ 278667	A	20001222	NZ 1995-278667	19950203
IL 112847	A	19991028	IL 1995-112847	19950302
ZA 9501909	A	19960909	ZA 1995-1909	19950308
US 5869511	A	19990209	US 1996-700431	19960905
FI 9603510	A	19960906	FI 1996-3510	19960906
NO 9603746	A	19961106	NO 1996-3746	19960906
NO 310496	B1	20010716		
PRIORITY APPLN. INFO.:			US 1994-209125	A 19940309
			WO 1995-IB78	W 19950203
OTHER SOURCE(S): CASREACT 124:117297; MARPAT 124:117297				


IT 167099-17-4P 167099-18-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of isoxazolines as TNF release inhibitors)
 RN 167099-17-4 CAPLUS
 CN 5-Isioxazolecarboxamide, 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydro-
 5-methyl-N-[(1S)-1-phenylethyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 167099-18-5 CAPLUS
 CN 5-Isioxazolecarboxamide, 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydro-
 5-methyl-N-[(1S)-1-phenylethyl]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:994642 CAPLUS
 DOCUMENT NUMBER: 124:86996
 ORIGINAL REFERENCE NO.: 124:16351a
 TITLE: Preparation of 3-(4-hydroxy-3,5-di-tert-butylphenyl)-2-isoxazolines as antirheumatics
 INVENTOR(S): Schwab, Wilfried; Anagnostopulos, Hiristo; Ryder, Bartlett Robert; Schleyerbach, Rudolf; Weithmann, Klaus Ulrich
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Ger. Offen., 50 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4408084	A1	19950914	DE 1994-4408084	19940310
TW 419469	B	20010121	TW 1994-83108551	19940916

CA 2185004	A1	19950914	CA 1995-2185004	19950303
WO 9524397	A1	19950914	WO 1995-EP784	19950303
W: AU, CA, CN, FI, HU, JP, KR, NO, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9519481	A	19950925	AU 1995-19481	19950303
AU 684914	B2	19980108		
EP 749429	A1	19961227	EP 1995-912197	19950303
EP 749429	B1	19990630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1143956	A	19970226	CN 1995-192004	19950303
CN 1056836	C	20000927		
HU 76481	A2	19970929	HU 1996-2458	19950303
HU 225499	B1	20070129		
JP 09509951	T	19971007	JP 1995-523212	19950303
AT 181733	T	19990715	AT 1995-912197	19950303
ES 2135046	T3	19991016	ES 1995-912197	19950303
NO 9603560	A	19960826	NO 1996-3560	19960826
FI 9603508	A	19960906	FI 1996-3508	19960906
US 5814627	A	19980929	US 1996-704743	19961119
PRIORITY APPLN. INFO.:			DE 1994-4408084	A 19940310
			WO 1995-EP784	W 19950303


OTHER SOURCE(S): CASREACT 124:86996; MARPAT 124:86996

IT 172412-91-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(4-hydroxy-3,5-di-tert-butylphenyl)-2-isoxazolines as antirheumatics)

RN 172412-91-8 CAPLUS

CN 5-Isioxazolecarboxamide, 3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4,5-dihydro-N-[(4-hydroxy-3,5-dimethylphenyl)methyl]-5-methyl- (CA INDEX NAME)



L12 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:763862 CAPLUS

DOCUMENT NUMBER: 123:169611

ORIGINAL REFERENCE NO.: 123:30283a,30286a

TITLE: Preparation of 3-aryl-2-isoxazolines as antiinflammatory agents

INVENTOR(S): Kleinman, Edward F.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9514680	A1	19950601	WO 1994-IB313	19941012
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2177375	A1	19950601	CA 1994-2177375	19941012
EP 730587	A1	19960911	EP 1994-927778	19941012
EP 730587	B1	19991208		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09500146	T	19970107	JP 1995-514932	19941012
JP 2818820	B2	19981030		
AT 187447	T	19991215	AT 1994-927778	19941012
ES 2139754	T3	20000216	ES 1994-927778	19941012
PT 730587	T	20000531	PT 1994-927778	19941012
FI 9405556	A	19950527	FI 1994-5556	19941125
US 5686434	A	19971111	US 1996-640945	19960515
GR 3032506	T3	20000531	GR 2000-400200	20000127
PRIORITY APPLN. INFO.:			US 1993-157241	A1 19931126
			WO 1994-IB313	W 19941012


OTHER SOURCE(S): CASREACT 123:169611; MARPAT 123:169611

IT 167099-35-6P 167099-36-7P 167099-37-8P
 167099-38-9P 167099-39-0P 167099-40-3P
 167099-42-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of 3-aryl-2-isoxazolines as PDE type IV
 inhibitors)

RN 167099-35-6 CAPLUS


CN 5-Isioxazolecarboxamide, 4,5-dihydro-3-[4-methoxy-3-[(5-
 phenylpentyl)oxy]phenyl]-5-methyl-N-(1-phenylethyl)- (CA INDEX NAME)



RN 167099-36-7 CAPLUS

CN 5-Isioxazolecarboxamide, 4,5-dihydro-3-[4-methoxy-3-[(5-
 phenylpentyl)oxy]phenyl]-5-methyl-N-(1-phenylethyl)-, [S-(R*,S*)]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 167099-37-8 CAPLUS

CN 5-Isoxazolecarboxamide, 4,5-dihydro-3-[4-methoxy-3-[(5-phenylpentyl)oxy]phenyl]-5-methyl-N-(1-phenylethyl)-, [R-(R*,R*)]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 167099-38-9 CAPLUS

CN 5-Isoxazolecarboxamide, 5-ethyl-4,5-dihydro-3-[4-methoxy-3-[(5-phenylpentyl)oxy]phenyl]-N-(1-phenylethyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167099-39-0 CAPLUS

CN 5-Isoxazolecarboxamide, 5-ethyl-4,5-dihydro-3-[4-methoxy-3-[(5-phenylpentyl)oxy]phenyl]-N-(1-phenylethyl)-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167099-40-3 CAPLUS


CN 5-Isioxazolecarboxamide, 4,5-dihydro-3-[4-methoxy-3-[(5-phenylpentyl)oxy]phenyl]-N-(1-phenylethyl)-5-propyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167099-42-5 CAPLUS

CN 5-Isioxazolecarboxamide, 3-[3-(bicyclo[2.2.1]hept-2-yloxy)-4-methoxyphenyl]-4,5-dihydro-5-methyl-N-(1-phenylethyl)- (CA INDEX NAME)



L12 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:763861 CAPLUS
DOCUMENT NUMBER: 123:169610
ORIGINAL REFERENCE NO.: 123:30283a,30286a
TITLE: Isoxazoline compounds as antiinflammatory agents
INVENTOR(S): Kleinman, Edward F.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9514681	A1	19950601	WO 1994-IB333	19941026
W: AU, BR, CA, CN, CZ, HU, JP, KR, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2176255	A1	19950601	CA 1994-2176255	19941026
CA 2176255	C	19990223		
AU 9478218	A	19950613	AU 1994-78218	19941026
AU 687452	B2	19980226		
EP 730588	A1	19960911	EP 1994-929001	19941026
EP 730588	B1	19970702		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1136314	A	19961120	CN 1994-194274	19941026
CN 1046274	C	19991110		
JP 09500147	T	19970107	JP 1994-514933	19941026
BR 9408174	A	19970527	BR 1994-8174	19941026
AT 154932	T	19970715	AT 1994-929001	19941026
ES 2104424	T3	19971001	ES 1994-929001	19941026
HU 76784	A2	19971128	HU 1996-1412	19941026
CZ 283564	B6	19980513	CZ 1996-1510	19941026
IL 111670	A	19980816	IL 1994-111670	19941117
FI 9405557	A	19950527	FI 1994-5557	19941125
ZA 9409379	A	19960527	ZA 1994-9379	19941125
US 5716967	A	19980210	US 1996-640944	19960515
NO 9602127	A	19960524	NO 1996-2127	19960524
PRIORITY APPLN. INFO.:			US 1993-157248	A2 19931126
			US 1994-262086	A2 19940617
			WO 1994-IB333	W 19941026

OTHER SOURCE(S): CASREACT 123:169610; MARPAT 123:169610

IT 167099-17-4P 167099-18-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of isoxazolines as PDE type IV inhibitors)

RN 167099-17-4 CAPLUS


CN 5-Isoxazolecarboxamide, 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydro-5-methyl-N-[(1S)-1-phenylethyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 167099-18-5 CAPLUS
 CN 5-Isioxazolecarboxamide, 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydro-5-methyl-N-[(1S)-1-phenylethyl]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



=> FIL STNGUIDE
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
89.61	819.47

FILE 'STNGUIDE' ENTERED AT 17:21:55 ON 02 OCT 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Sep 26, 2008 (20080926/UP).

=>
 Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:
 TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America

NEWS	2	APR	04	STN AnaVist, Version 1, to be discontinued
NEWS	3	APR	15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	4	APR	28	EMBASE Controlled Term thesaurus enhanced
NEWS	5	APR	28	IMSRESEARCH reloaded with enhancements
NEWS	6	MAY	30	INPAFAMDB now available on STN for patent family searching
NEWS	7	MAY	30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	8	JUN	06	EPFULL enhanced with 260,000 English abstracts
NEWS	9	JUN	06	KOREAPAT updated with 41,000 documents
NEWS	10	JUN	13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	11	JUN	19	CAS REGISTRY includes selected substances from web-based collections
NEWS	12	JUN	25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	13	JUN	30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	14	JUN	30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	15	JUN	30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	16	JUN	30	STN AnaVist enhanced with database content from EPFULL
NEWS	17	JUL	28	CA/CAPplus patent coverage enhanced
NEWS	18	JUL	28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	19	JUL	28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	20	JUL	28	STN Viewer performance improved
NEWS	21	AUG	01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	22	AUG	13	CA/CAPplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	23	AUG	15	CAOLD to be discontinued on December 31, 2008
NEWS	24	AUG	15	CAPplus currency for Korean patents enhanced
NEWS	25	AUG	25	CA/CAPplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS	26	AUG	27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	27	SEP	18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	28	SEP	25	CA/CAPplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	29	SEP	26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	30	SEP	29	IFICLS enhanced with new super search field
NEWS	31	SEP	29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	32	SEP	30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS EXPRESS	JUNE	27	08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability			
NEWS LOGIN	Welcome Banner and News Items			
NEWS IPC8	For general information regarding STN implementation of IPC 8			

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:59:54 ON 03 OCT 2008

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:00:06 ON 03 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2008 HIGHEST RN 1056151-32-6

DICTIONARY FILE UPDATES: 1 OCT 2008 HIGHEST RN 1056151-32-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10568503j.str



```

chain nodes :
6 7 8 9 10 11 12
ring nodes :
1 2 3 4 5
chain bonds :
5-6 6-7 6-8 7-9 9-10 9-11 9-12
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
2-3 6-7 6-8 7-9
exact bonds :
1-2 1-5 3-4 4-5 5-6 9-10 9-11 9-12
isolated ring systems :
containing 1 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 11:00:18 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 309 TO ITERATE

100.0% PROCESSED 309 ITERATIONS

33 ANSWERS

SEARCH TIME: 00.00.01

L2 33 SEA SSS FUL L1

=> file capl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 11:00:20 ON 03 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Oct 2008 VOL 149 ISS 15

FILE LAST UPDATED: 2 Oct 2008 (20081002/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 12

L3 3 L2

=> d 13 ibib

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:151203 CAPLUS

DOCUMENT NUMBER: 144:233059

TITLE: Preparation of heterocyclic derivatives as anti-inflammatory agents

INVENTOR(S): Palle, Venkata P.; Verma, Ashwani Kumar; Salman, Mohammad; Singh, Rakesh Kumar; Waman, Yogesh Bhaskarrao; Sharma, Geeta; Ray, Abhijit

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006016237	A2	20060216	WO 2005-IB2292	20050802
WO 2006016237	A3	20060526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-598621P P 20040804
 OTHER SOURCE(S): MARPAT 144:233059

=> d 13 2-3 ibib

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:921226 CAPLUS
 DOCUMENT NUMBER: 143:381666
 TITLE: Exploring the Scope of the 29G12 Antibody Catalyzed
 1,3-Dipolar Cycloaddition Reaction
 AUTHOR(S): Toker, Jonathan D.; Tremblay, Martin R.;
 Yli-Kauhaluoma, Jari; Wentworth, Anita D.; Zhou, Bin;
 Wentworth, Paul, Jr.; Janda, Kim D.
 CORPORATE SOURCE: Department of Chemistry and the Skaggs Institute for
 Chemical Biology, The Scripps Research Institute, La
 Jolla, CA, 92037, USA
 SOURCE: Journal of Organic Chemistry (2005), 70(20), 7810-7815
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:381666
 REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:22567 CAPLUS
 DOCUMENT NUMBER: 124:203064
 ORIGINAL REFERENCE NO.: 124:37561a,37564a
 TITLE: Synthesis and inhibitory activities of HIV-1 protease
 inhibitors containing 2-isoxazoline derivatives
 AUTHOR(S): Chung, Yong Jun; Kim, Do-Hyung; Choi, Kwan Yong; Kim,
 Byeang Hyeon
 CORPORATE SOURCE: Dep. of Chemistry, Pohang Univ. of Science and
 Technology, Pohang, 790-784, S. Korea
 SOURCE: Korean Journal of Medicinal Chemistry (1995), 5(2),
 141-61
 CODEN: KJMCE7; ISSN: 1225-0058
 PUBLISHER: Korean Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

=> FIL STNGUIDE
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
4.11	182.68

FILE 'STNGUIDE' ENTERED AT 11:00:54 ON 03 OCT 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Sep 26, 2008 (20080926/UP).

=> d 13 3 hitstr

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

IT 174357-32-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and HIV protease inhibitory activity of isoxazoline and hydroxyethylene pseudodipeptides)

RN 174357-32-5 CAPLUS

CN Carbamic acid, [3-amino-1-[[[2-[5-[[[(1,1-dimethylethyl)amino]carbonyl]-4,5-dihydro-3-isoxazolyl]-2-hydroxy-1-(phenylmethyl)ethyl]amino]carbonyl]-3-oxopropyl]-, phenylmethyl ester, [5S-[3[1R*(R*),2S*],5R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 174357-24-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and HIV protease inhibitory activity of isoxazoline and hydroxyethylene pseudodipeptides)

RN 174357-24-5 CAPLUS

CN 3-Oxazolidinecarboxylic acid, 5-[5-[[[(1,1-dimethylethyl)amino]carbonyl]-4,5-dihydro-3-isoxazolyl]-2,2-dimethyl-4-(phenylmethyl)-, 1,1-dimethylethyl ester, [4S-[4 α ,5 β (R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>